bioMerieux (OTCMKTS:BMXMF - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $147.20, but opened at $140.25. bioMerieux shares last traded at $140.25, with a volume of 50 shares trading hands.
Wall Street Analyst Weigh In
Separately, Royal Bank Of Canada cut shares of bioMerieux from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, bioMerieux presently has an average rating of "Hold".
View Our Latest Research Report on BMXMF
bioMerieux Trading Down 4.7%
The business's fifty day moving average is $143.99 and its 200 day moving average is $133.36. The company has a current ratio of 2.20, a quick ratio of 1.29 and a debt-to-equity ratio of 0.08.
bioMerieux Company Profile
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider bioMerieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.
While bioMerieux currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
